GlassScriptPhysician profile
Brian Keith Stansell
NPI 1841230729
$19,089.12
in general payments reported to CMS, 2019-2025
31 companies · $8,088 in 2025
The $8,088 reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,892 · 2020: $586 · 2021: $850 · 2022: $1,126 · 2023: $2,928 · 2024: $1,618 · 2025: $8,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,980 · Food and Beverage: $4,749 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,400 · Travel and Lodging: $1,205 · Consulting Fee: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,980.00 |
| Food and Beverage | $4,749.16 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,400.00 |
| Travel and Lodging | $1,204.82 |
| Consulting Fee | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $6,788.46 | 2023-2025 | Odactra, Grastek, Ragwitek |
| Supernus Pharmaceuticals, INC. | $4,271.91 | 2019-2025 | Qelbree, Qelbree |
| Corium, LLC | $2,898.02 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $1,315.84 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $542.27 | 2019-2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $521.98 | 2019-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Glaxosmithkline, LLC. | $317.92 | 2019-2025 | Bexsero |
| Kowa Pharmaceuticals America, INC. | $259.72 | 2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $259.67 | 2024-2025 | |
| Sanofi Pasteur INC. | $233.83 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $218.88 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $212.97 | 2019-2022 | |
| Pfizer INC. | $180.70 | 2019-2025 | |
| Verrica Pharmaceuticals INC. | $144.88 | 2024 | Ycanth |
| Merck Sharp & Dohme LLC | $125.94 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $98.96 | 2021-2024 | Flumist Quadrivalent |
| Genentech USA, INC. | $87.60 | 2019-2020 | |
| Adlon Therapeutics L.P. | $82.03 | 2020-2021 | |
| Galderma Laboratories, L.P. | $76.08 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $61.72 | 2023-2025 | Daybue |
| Shire North American Group INC | $60.87 | 2019 | |
| Kaleo, INC. | $48.36 | 2021-2023 | Auvi-Q |
| Sobi, INC | $44.46 | 2019-2020 | |
| Hologic Sales and Service, LLC | $42.65 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $41.51 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $30.10 | 2019 | |
| Meridian Bioscience INC. | $29.24 | 2020 | |
| Seqirus USA INC | $28.13 | 2021-2022 | |
| Rhodes Pharmaceuticals L.P. | $24.29 | 2019 | |
| Organon LLC | $22.19 | 2025 | |
| Vertical Pharmaceuticals, LLC | $17.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Stansell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.